No 10Y consistency score yet for revenue — the year-earlier revenue was zero, negative or too small a base to compare against in 14 of the 30 quarters in the window, leaving 16 comparable quarters; at least 28 are needed.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annualized revenue (TTM) · by quarter, last 31
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T14:31:54.742Z. Latest historical point 2025-07-29. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow. Quote observation: 2026-10-06T14:31:54.742Z. Latest historical point 2025-07-29. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Quote observation: 2026-10-06T14:31:54.742Z. Latest historical point 2025-07-29. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter operating cash flow / FMP quote market capitalization × 100. Quote observation: 2026-10-06T14:31:54.742Z. Latest historical point 2025-07-29. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter free cash flow / FMP quote market capitalization × 100. Quote observation: 2026-10-06T14:31:54.742Z. Latest historical point 2025-07-29. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Fulcrum Therapeutics, Inc. (FULC) stock was $3.70 as of Oct 6, 2026, 10:30 AM EDT, down 0.40% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -59.6% · 3-year avg -4.3%/yr · 5-year avg -31.7%/yr
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical firm committed to developing life-improving treatments for patients in the United States afflicted by genetically defined diseases with significant unmet medical needs.
Biotechnology · Cambridge, MA
Next Earnings Date
Oct 29, 2026
23 days away
EPS Estimate
-0.07
Revenue Est.
N/A
Last Quarter Results
EPS
$-0.22
vs Estimate
$-0.22
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1FULC | $281.92M | $3.69 | -0.40% | -59.59% | -31.70% | N/A | N/A |
| 2ABEO | $281.84M | $4.95 | -3.23% | -5.53% | -26.46% | -29.45% | vs FULC |
| 3LRMR | $286.20M | $2.75 | -3.67% | -41.12% | -23.91% | -23.59% | vs FULC |
| 4INDP | $275.74M | $2.44 | -2.99% | -23.14% | -58.32% | -57.48% | vs FULC |
| 5ACB | $274.71M | $4.43 | -0.56% | -20.97% | -42.83% | -30.23% | vs FULC |
| 6BBOT | $289.59M | $3.62 | +0.42% | -70.70% | N/A | N/A | vs FULC |
forward FY estimate
N/A
$0.00
vs Estimate
$0.00
Consensus Rating
Based on 3 analysts
Average Price Target
$3.67
-0.8% downside
Low
$3.00
Current
$3.69
High
$4.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.09 | $-0.07 | $-0.05 | 2 |
| Quarter ending Dec 2026 | $-0.05 | $-0.05 | $-0.05 | 1 |
| Quarter ending Mar 2027 | $-0.29 | $-0.29 | $-0.29 | 1 |
| Quarter ending Jun 2027 | $-0.29 | $-0.29 | $-0.29 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-0.81 | $-0.60 | $-0.49 | 3 |
| FY 2027 | $-0.26 | $-0.12 | $-0.04 | 5 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Dec 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Mar 2027 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Jun 2027 | $0.00 | $0.00 | $0.00 | 0 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $311890.00 | $311890.00 | $311890.00 | 5 |
| FY 2027 | $361.24M | $361.24M | $361.24M | 4 |
